Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure.
Aspergillus
CAPA
COVID-19
SARS-CoV-2
histology
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
09
06
2021
received:
28
04
2021
accepted:
19
06
2021
pubmed:
23
6
2021
medline:
30
9
2021
entrez:
22
6
2021
Statut:
ppublish
Résumé
An increasing number of reports have described the COVID-19-associated pulmonary aspergillosis (CAPA) as being a further contributing factor to mortality. Based on a recent consensus statement supported by international medical mycology societies, it has been proposed to define CAPA as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Considering current challenges associated with proven diagnoses, there is pressing need to study the epidemiology of proven CAPA. We report the incidence of histologically diagnosed CAPA in a series of 45 consecutive COVID-19 laboratory-confirmed autopsies, performed at Padova University Hospital during the first and second wave of the pandemic. Clinical data, laboratory data and radiological features were also collected for each case. Proven CAPA was detected in 9 (20%) cases, mainly in the second wave of the pandemic (7/17 vs. 2/28 of the first wave). The population of CAPA patients consisted of seven males and two females, with a median age of 74 years. Seven patients were admitted to the intensive care unit. All patients had at least two comorbidities, and concomitant lung diseases were detected in three cases. We found a high frequency of proven CAPA among patients with severe COVID-19 thus confirming at least in part the alarming epidemiological data of this important complication recently reported as probable CAPA.
Sections du résumé
BACKGROUND
BACKGROUND
An increasing number of reports have described the COVID-19-associated pulmonary aspergillosis (CAPA) as being a further contributing factor to mortality. Based on a recent consensus statement supported by international medical mycology societies, it has been proposed to define CAPA as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Considering current challenges associated with proven diagnoses, there is pressing need to study the epidemiology of proven CAPA.
METHODS
METHODS
We report the incidence of histologically diagnosed CAPA in a series of 45 consecutive COVID-19 laboratory-confirmed autopsies, performed at Padova University Hospital during the first and second wave of the pandemic. Clinical data, laboratory data and radiological features were also collected for each case.
RESULTS
RESULTS
Proven CAPA was detected in 9 (20%) cases, mainly in the second wave of the pandemic (7/17 vs. 2/28 of the first wave). The population of CAPA patients consisted of seven males and two females, with a median age of 74 years. Seven patients were admitted to the intensive care unit. All patients had at least two comorbidities, and concomitant lung diseases were detected in three cases.
CONCLUSION
CONCLUSIONS
We found a high frequency of proven CAPA among patients with severe COVID-19 thus confirming at least in part the alarming epidemiological data of this important complication recently reported as probable CAPA.
Identifiants
pubmed: 34157166
doi: 10.1111/myc.13342
pmc: PMC8446949
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1223-1229Subventions
Organisme : Fellowship from the University of Padua/Intesa San Paolo Vita Bank
ID : 2020A08
Organisme : University of Padova (Intesa San Paolo Vita bank)
ID : 2020A08
Informations de copyright
© 2021 The Authors. Mycoses published by Wiley-VCH GmbH.
Références
Lancet Respir Med. 2020 Jun;8(6):e48-e49
pubmed: 32445626
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
Am J Respir Crit Care Med. 2020 Jul 1;202(1):132-135
pubmed: 32396381
J Pathol. 2021 Jun;254(2):173-184
pubmed: 33626204
Mod Pathol. 2020 Nov;33(11):2156-2168
pubmed: 32879413
Crit Care. 2020 Sep 1;24(1):538
pubmed: 32867810
Mycoses. 2021 Oct;64(10):1223-1229
pubmed: 34157166
Front Med (Lausanne). 2021 Apr 01;8:637872
pubmed: 33869252
Virchows Arch. 2020 Sep;477(3):359-372
pubmed: 32642842
J Cardiothorac Vasc Anesth. 2020 Sep;34(9):2341-2345
pubmed: 32425461
Eur Radiol. 2020 Dec;30(12):6808-6817
pubmed: 32623505
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33263058
Mycoses. 2020 Aug;63(8):766-770
pubmed: 32585069
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Thorac Oncol. 2020 Nov;15(11):1782-1785
pubmed: 32866652
Clin Infect Dis. 2021 Oct 5;73(7):e1634-e1644
pubmed: 32860682